

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hepalink

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9989)

VOLUNTARY ANNOUNCEMENT

THE COMPANY'S H SHARES WILL BE NEWLY INCLUDED IN THE FTSE GLOBAL EQUITY INDEX SERIES

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”), together with its subsidiaries referred to as the “**Group**”) to inform the shareholders and potential investors of the Company about the advancement of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company's H shares will be newly included in the FTSE Global Equity Index cap index, which will become effective on December 21, 2020.

INFORMATION ABOUT FTSE GEIS

FTSE GEIS includes over 16,000 large, mid, small, and emerging markets globally, with a wide range of markets and market segments.

Shareholders and potential investors of the Company dealing in the securities of the Company should not be regarded as